This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2026
Good day, everyone, and welcome to the CINDEX third quarter 2026 earnings conference call. The call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star five during the call. At this time, I would like to turn the call over to Sharon Klahre, head of investor relations at CINDEX Pharmaceuticals.
Thank you, Operator. Welcome and thank you all for joining us today for a review of Syndax's third quarter 2026 financial and operating results. I'm Sharon Klahre and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer, Steve Closter, Chief Commercial Officer, Dr. Nick Botwood, Head of R&D and Chief Medical Officer, and Keith Goldan, Chief Financial Officer. These calls accompanied by a slide deck that has been posted on the investor page of the company's website. You can now turn to our forward-looking statements on slide two. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in the company's most recent quarterly report on Form 10-Q, as well as other reports filed with the SEC. Any forward-looking statements made represent our views as of today, November 2, 2026 only. A replay of this call will be available on the company's website, www.syndex.com, following its completion. With that, I am pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndex.
Thank you, Sharon, and good afternoon, everyone. Let's start on slide three. Syndex delivered another strong quarter of commercial growth and pipeline momentum. Total revenue reached $83 million this quarter, up 82% year over year. Demand for both medicines is robust, and we are moving decisively towards profitability. Revuforge net revenue grew to $61 million in the third quarter, underscoring our market leadership in both relapse refractory NPM1 and KMT2A acute leukemia. Similar to prior quarters, we expect Revuforge to account for the vast majority, more than 80% of the revenue for the class this quarter, a leading position we intend to carry forward. Thank you very much. As patients pause treatment to receive a transplant, this creates a short-term headwind that will become a long-term tailwind as more patients resume therapy post-transplant, extending the average duration of therapy and driving durable growth for the franchise. Every indicator of Revuforge demand is positive. The latest data are clear. We continue to lead new men and inhibitor starts across every age group, including age groups where NPM1 is predominant. With an unmatched body of clinical trial and real-world evidence and two years of deep clinician experience in the commercial setting, we are confident Reviforge will remain the menin inhibitor of choice for all menin-dependent acute leukemias. The clinical impact of our medicine was showcased last week when Reviforge received the prestigious Best Product for Rare Orphan Diseases Award from the Galen Foundation on the heels of being recognized by Time as one of the best innovations of 2026. These awards are a testament to our leadership in men in inhibition and the profound difference we've made for patients with some of the most aggressive forms of acute leukemia. Looking ahead, multiple value-driving Revuforge milestones are on deck. As in prior years, Revuforge will have a leading presence at the American Society of Hematology, or ASH, annual meeting in December. New data will be presented from multiple clinical trials and real-world studies spanning the entire acute leukemia treatment continuum, including new frontline combination data that highlight the potential for our ongoing pivotal frontline trials to deliver transformative results. We remain well positioned to be the first to frontline with a Mennon inhibitor, an area of high unmet need, and substantial commercial opportunity. With anticipated frontline indications, we expect Gravity Forge could exceed $2 billion in peak annual net revenue in the U.S. alone. Nearer term, we expect to publish Reviforge data in relapse refractory NUP98 rearranged acute leukemia in the fourth quarter. This landmark publication will inform clinical practice and could support guideline inclusion in a patient population with high unmet need. NUP98 rearrangements, estimated to be found in approximately 2% to 5% of AML cases, are associated with a poor prognosis and resistance to conventional therapies. No targeted treatments have been approved for these patients. Thank you very much. Turning to Nick Timbo in chronic graft-versus-host disease, or GVHD. Nick Timbo net revenue grew to $67 million in the third quarter, up 47% year-over-year and 12% quarter-over-quarter. Our 50% share of Nick Timbo net profit delivered $23 million in collaboration revenue, a meaningful contribution to our bottom line. Collaboration revenue to Syndex is now annualizing at over $90 million, and we expect it to keep growing as we further penetrate fourth- and third-line chronic GVHD. Positive results from the ongoing combination trials of Nictimbo and frontline chronic GVHD could set a new treatment paradigm and unlock another multibillion-dollar opportunity in the near term. Beyond moving Reviforge and Nictimbo into earlier lines of treatment, we are advancing our mutant-selective allosteric EGFR inhibitor for non-small-cell-length lung cancer and our next-generation inhibitor for menin myelofibrosis. Both molecules are on track to enter the clinic next year. Each brings a novel mechanism of action to diseases with high unmet need, where we can efficiently generate clinical data that inform and de-risk further development. Thank you for joining us. Before I turn the call over to Steve, I want to sincerely thank Keith Goldan for his many contributions, including leading Syndex's financial and capital strategy during an important time in the company's history and spearheading numerous long-term growth initiatives. After more than four years of the company and over 30 years in the industry, Keith Goldan has decided to retire as Chief Financial Officer. I'm pleased to welcome Aaron Andre as our new CFO effective Monday, November 9th. Aaron brings extensive financial and operational leadership experience in biopharmaceutical companies, expanding financial management, corporate strategy, and commercialization. I will now turn the call over to Steve to discuss our commercial results in more detail.
You're reading a preview of the SNDX Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing